Myriad Genetics, Illumina expand partnership for HRD testing access

Myriad Genetics (MYGN) and Illumina (ILMN) announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency testing in the United States. Under the agreement, Illumina TruSight Oncology 500 HRD, a research-use-only test, is now available in the US. The expanded partnership also establishes a unique companion diagnostic alliance for the pharmaceutical industry, which will enable more clinical research for gene-based, targeted therapies.Under this strategic alliance, Illumina and Myriad will seek joint HRD companion diagnostics partnerships with pharmaceutical companies worldwide. The joint HRD CDx alliance will aim to pursue HRD regulatory approvals for both the MyChoice HRD Assay companion diagnostic and a future clinical in vitro diagnostic test based off the TSO 500 HRD Assay.